Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Fig. 4

The enrichment of CD8+CD103+TRM in the MPR group. (A) Single-cell analysis divided 42,678 cells into 15 sub-clusters. Treg, regulatory T cells; T-STR, stress response state T cells; Tfh, T follicular helper cells. (B) Expression of T cell subset-defining genes. (C) Distribution image of CD8+CD103+TRM in the MPR versus non-MPR group. (D) Statistical chart of the proportion of CD8+CD103+TRM in single-cell analysis in the MPR versus non-MPR group. (E) Representative images of TRM in immunofluorescence analysis. Left: the MPR group; Right: the non-MPR group. (F) Statistical chart of TRM of immunofluorescence analysis in the MPR versus non-MPR group. Scale bars, 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us